不破20日均线，大盘回踩属正常调整

Market Overview - A-shares showed mixed performance on July 15, with the Shanghai Composite Index down 0.42% closing at 3505 points, while the Shenzhen Component Index rose 0.56% to 10744.56 points, and the ChiNext Index increased by 1.73% to 2235.05 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 161.21 billion yuan, an increase of 153.3 billion yuan compared to the previous day [1] - The market was influenced by significant declines in blue-chip stocks such as banks and real estate, leading to a drop in the Shanghai Composite Index, which briefly fell below the 10-day moving average [1] Sector Performance - Most industry sectors experienced declines, with jewelry, coal, electricity, mining, energy metals, photovoltaic equipment, pesticides, and liquor industries among the hardest hit [1] - Conversely, the internet services sector showed notable gains, contributing to the overall mixed market performance [1] Individual Stock Highlights - Despite the overall market downturn, the ChiNext Index surged nearly 2%, primarily driven by the technology sector [2] - Nvidia's CEO announced that the U.S. government approved export licenses for the company to sell H20 chips to China, which positively impacted the A-share market, particularly in the artificial intelligence sector [2] Technical Analysis - The Shanghai Composite Index displayed signs of volatility, with a long upper shadow followed by a long lower shadow, indicating intense market contention between buyers and sellers [2] - The index's strongest support level is identified around the 20-day moving average at approximately 3452 points, suggesting that a rebound could occur if the index approaches this level without breaking it [2] Company-Specific Insights - Nanjing New Pharmaceutical Co., Ltd. (南新制药) saw a significant stock price increase despite unimpressive financial data, with a Q1 2025 earnings per share of -0.03 yuan and a net profit of -8.0283 million yuan, reflecting a year-on-year decline of 143.66% [3] - The recent stock surge is attributed to the company's innovative drug developments, particularly the inhalation solution for treating influenza, which has completed Phase II clinical trials and is preparing for Phase III trials [3]